Phaseline

Targets › BTN3A1

BTN3A1 (Butyrophilin subfamily 3 member A1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2029.

Plays a role in T-cell activation and in the adaptive immune response. Regulates the proliferation of activated T-cells. (UniProt, O00481)

Open in Phaseline: the race on BTN3A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chinese PLA General HospitalAllogeneic TCR-enhanced Vδ2 T cell Injection
Allogeneic genetically engineered Vδ2 T cells with enhanced BTN protein-binding moiety for
BTN3A1Phase 1Hematologic MalignancyJun 2029

Conditions

Hematologic Malignancy (1)

Modalities

mixed (1)

Companies

Chinese PLA General Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.